Vivus Inc (NASDAQ:VVUS) Downgrade

Vivus Inc (NASDAQ:VVUS) was downgraded by investment analysts at WallachBeth Capital from “Buy” rating to “Hold” rating in a research report revealed on Wednesday morning.

Out of 3 analysts covering Vivus Inc, 1 rate it a Buy, 4 indicate a Hold while 0 suggest a Sell. The highest target is $18 and the lowest is $1 according to Thomson/First Call. The 12-month mean target is $7.27, which means upside potential of 430.66% over the current price.

NASDAQ:VVUS Price Chart & Trend

The stock price of Vivus Inc plummeted 35.07% over the last 200 days, and is in strong down trend. In the last 50 and 100 days, Vivus Inc is up 30.48% and up 37%, respectively. Our stocks momentum model is shown on the price chart below.

Source: RightEdge Systems, Yahoo Split & Dividend Adjusted Data and OctaFinance Trading Models

Institutional Ownership

Tahithromos L.L.C. had the largest stake with ownership of 3.97 million shares as of q2 2015 for 12.87% of the portfolio. Meditor Group Ltd is another notably bullish active investment manager who is having 2.97 million shares of Vivus Inc or 4.83% of their portfolio. Moreover, North Tide Capital Llc have 2.13% of their portfolio invested in the company for 12.50 million shares. The Connecticut-based fund Sarissa Capital Management Lp disclosed it had acquired so far a stake worth about 1.4% of the active investment manager’s stock portfolio in Vivus Inc. The California-based fund Empyrean Capital Partners Lp is also positive about the stock, possessing 2.57 million shares or 0.22% of their portfolio.Over the last 6 months, Vivus Inc NASDAQ:VVUS has seen 0 insider purchases, and 2 insider sales. The net result was for 2 transactions, worth $9,581.

Vivus Inc (NASDAQ:VVUS) Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Vivus Inc (NASDAQ:VVUS) closed at $1.37 yesterday. A total of 1.02 million shares of the company’s stock traded hands. This is down from average of 1.19 million shares. Vivus Inc has a 52 week low of $0.92 and a 52 week high of $2.65. The company has a market cap of $130.24 million and a P/E ratio of 0.

Get the latest Vivus Inc (NASDAQ:VVUS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Will Wallachbeth Capital Downgrade to “Hold” from “Buy” Be a Headwind For Vivus Inc (NASDAQ:VVUS) Stock Today? appeared first on Octafinance.